首页> 外文期刊>Clinical and experimental hypertension: CEH >Home blood pressure and cardiovascular outcomes in very elderly patients receiving antihypertensive drug therapy: a subgroup analysis of Home blood pressure measurement with Olmesartan Naive patients to Establish Standard Target blood pressure (HONEST) study
【24h】

Home blood pressure and cardiovascular outcomes in very elderly patients receiving antihypertensive drug therapy: a subgroup analysis of Home blood pressure measurement with Olmesartan Naive patients to Establish Standard Target blood pressure (HONEST) study

机译:家庭血压和心血管成果在非常老年患者接受抗高血压药物治疗:亚群分析家庭血压测量与Olmesartan天真患者建立标准目标血压(诚实)研究

获取原文
获取原文并翻译 | 示例
           

摘要

The appropriate target blood pressure (BP) in elderly patients with hypertension remains uncertain. We investigated the relationship between morning home systolic blood pressure (MHSBP) during follow-up and cardiovascular (CV) risk in outpatients receiving olmesartan-based treatment aged <75 years (n = 16799) and >75 years (n = 4792) in the HONEST study. In the follow-up period (mean 2.02 years), the risk for major CV events was significantly higher in patients with MHSBP s155 mmHg compared with <125 mmHg in both age groups in Cox proportional hazards model adjusted for other risk factors and there was no significant difference in trend between the two groups (interaction P = 0.9917 for MHSBP). Hazard ratios for CV events for 1-mmHg increase in MHSBP were similar in patients aged <75 years and in patients aged £75 years. The incidence of adverse drug reactions related to excessive BP lowering was lower in patients <75 years than in patients £75 years (0.73 vs 1.02%, P = 0.0461).In conclusion, the study suggests even in patients £75 years antihypertensive treatment targeting the same MHSBP levels in patients <75 years may be beneficial in reducing CV risk when treatment is tolerated.
机译:高血压患者的适当靶血压(BP)仍然不确定。我们调查了在随访期间的早期家庭收缩压(MHSBP)之间的关系(CV),接受基于Olmesartan的治疗的门诊患者<75岁(n = 16799)和> 75岁(n = 4792)诚实的学习。在随访期(平均2.02年)中,MHSBP S155mmhg患者的主要CV事件的风险显着高于Cox比例危险模型的125 mmHg,调整为其他风险因素,没有两组之间趋势的显着差异(MHSBP的相互作用P = 0.9917)。在75岁和75岁龄患者的患者中,MHSBP患者的1mmHg患者的CV事件的危险比率相似。与过量的BP降低相关的不良药物反应的发生率<75年比患者75岁(0.73 Vs 1.02%,P = 0.0461)。在结论中,甚至在患者均为75年的抗高血压治疗靶向患者患者同样的MHSBP水平<75岁可能是有益的,在耐受治疗时降低CV风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号